Exogenous surfactant therapy has been part of the routine care of preterm neonates with respiratory distress syndrome rds since the beginning of the 1990s. Peripheral intravenous iv catheter insertion for neonates may 2016 peripheral intravenous iv cannulation provides access for the administration of iv fluids including dextrose and parenteral nutrition, medications and blood products. Medication therapy in the neonatal population is complex as in addition to the common steps of drug use where risks can occur prescribing, transcribing, dispensing, preparation and administration, we must add other factors, such as lack of research on drug pharmacokinetics and pharmacodynamics in terms of weight and gestational age, and. Respiratory failure secondary to surfactant deficiency is a major cause of morbidity and mortality in low birth weight immature infants. Rds in a premature infant is defined as respiratory distress requiring more than 30% oxygen delivered by. Evolution of surfactant therapy for respiratory distress. Surfactant replacement therapy for neonates better safer. Practice frameworks and evidencebased practice guidelines erratum. Treatment of intubated infants on 30% or more oxygen whose clinical presentation and chest xray are consistent with rds. The term may also be used to refer to juveniles of other organisms. Preterm infants and surfactant effectiveness in clinical trials surfactant trials have included infants born between 23 and 34 weeks gestation andor with birth weight between 500 and 2000 g. Repletion with exogenous surfactant decreases mortality and thoracic air leaks and is a standard practice in the developed world.
Recent trials in infants with respiratory distress syndrome rds have not shown. Minimally invasive surfactant therapy with a gastric tube is as effective as the intubation, surfactant, and extubation technique in preterm babies marta aguar 1,2, mar. Single versus multipledose surfactant replacement therapy in neonates of 30 to 36 weeks gestation with respiratory distress syndrome. Therapy can usually be discontinued by postconceptional age usually 37 weeks, depending on the weight of the infant usually 18002000g, or if the infant has been apnea free for 7 days. Surfactant therapy has significantly changed clinical practice in neonatology over the last 25 years. Meconium aspiration syndrome mas, a common cause of respiratory failure in neonates, is associated with high mortality and morbidity. Despite its widespread use, the optimal method of surfactant administration in preterm infants has yet to be clearly determined. Pulmonary surfactant in newborn infants and children. Bolus surfactant therapy by tracheal catheterization, another method of administering surfactant while avoiding ventilation, has been developed in german neonatal units.
Respiratory failure secondary to surfactant deficiency is a major cause of morbidity and mortality in preterm neonates. Supporting parents and infants in neonatal intensive care. Beyond respiratory distress syndrome steven m donn md and jennifer dalton md introduction meconium aspiration syndrome surfactant replacement surfactant lavage bronchopulmonary dysplasia summary surfactant replacement therapy is a lifesaving treatment for preterm infants with respiratory. Surfactant in preterm infants introduction pulmonary surfactant is a complex mixture of phospholipids and proteins that serves to reduce alveolar surface tension. Surfactant replacement therapy for rds early rescue therapy should be practiced. Less approved recommendation for use of exogenous surfactant therapy includes intubated newborn infants with pulmonary haemorrhage which leads to clinical deterioration. Premature infants are at greatest risk of hemorrhage. The time of extubation was the same in both groups.
Surfactantreplacement therapy for respiratory distress in the. Objective to evaluate incidence of minimally invasive surfactant therapy mist failure, identify risk factors and assess the impact of mist failure on neonatal outcome. Surfactant therapy for neonatal respiratory distress syndrome. These are called less invasive surfactant administration lisa or minimally invasive surfactant therapy mist. Surfactant replacement therapy is recommended for intubated and ventilated newborns with respiratory distress syndrome. Clinical profile of newborns undergoing physical therapy in a. Policies are in place to guide how nicu staff will routinely mentor parents in the developmental care of their babies.
The statement summarizes the indications for surfactant replacement therapy. Many of the known risk factors for rds do not predict surfactant requirement. Pdf respiratory failure secondary to surfactant deficiency is a major cause of morbidity and mortality. Clinical practice guideline guideline coverage includes. The technique involves placement of a fine intratracheal catheter while babies keep spontaneously breathing on ncpap. Recommendations for neonatal surfactant therapy canadian. Minimally invasive surfactant therapy followed by cpap. When a baby comes out of the womb and the lungs are not developed yet, they require administration of surfactant in order to process oxygen and survive.
It is formed by type ii pneumocytes from about 20 weeks of gestation. In an effort to circumvent this problem, techniques of minimally invasive surfactant therapy have recently been investigated, aiming to administer surfactant to spontaneously breathing infants, allowing them to remain on cpap in the critical first days after birth and, hopefully, beyond. At 28 days of life, about half of the neonates in each group still needed oxygen or mechanical ventilation, and they had xray changes which were characteristic of bronchopulmonary dysplasia. Some of the indications for physical therapy in preterm and term neonates are the aspiration syndromes, respiratory distress syndrome, pneumonia, atelectasis and prevention of mechanical ventilation complications 2. Prophylactic surfactant administration is recommended for neonatal rds in which surfactant deficiency is suspected. Dec 28, 20 severe neonatal jaundice and its progression to kernicterus is a leading cause of death and disability among newborns in poorlyresourced countries, particularly in subsaharan africa. Early surfactant administration was associated with a lower risk of bpd rr 0. This outcome is achieved by reducing the surface tension and promoting alveolar stability during expiration. Thus, through bronchial clearance and pulmonary reexpansion techniques, physical therapy can provide improved respiratory function. Respiratory distress syndrome in newborn and surfactant. Beyond respiratory distress syndrome article pdf available in respiratory care 549. Study protocol open access treatment of neonatal jaundice. Access to xray and blood gas facilities is essential when considering the use of surfactant therapy. No differences were noted in the incidence of pda nec rop ivh among both groups.
Systemic cooling for neuroprotection in neonates 35 weeks gestional. Surfactant replacement therapy is a lifesaving treatment for preterm infants with respiratory distress syndrome, a disorder characterized by surfactant deficiency. In addition to respiratory distress syndrome, other neonatal respiratory disorders are. Join our mailing list click the button below to join the nant mailing list and receive our weekly newsletter. Therapeutic hypothermia is recommended for moderate and severe neonatal encephalopathy, but is being applied to a wider range of neonates than originally envisaged. Surfactant replacement therapy for preterm and term. Results for surfactant in neonates 1 10 of 92 sorted by relevance date. Surfactant replacement therapy improved oxygenation in the study subjects, suggesting that surfactant may have a role in the treatment of severe mas in term and nearterm infants.
Minimallyinvasive surfactant therapy in preterm infants. The fluid and electrolyte requirements of the neonate are unique due to fluids. Surfactant therapy and antibiotics in neonates with. Efficacy and safety of surfactant replacement therapy for. Surfactant replacement therapy, either as a rescue treatment or a prophylactic natural surfactant therapy, reduces mortality evidence level 1a table 1 and several aspects of morbidity in babies with rds 5. Guidelines for surfactant administration surfactant replacement. No association was observed in the risk of severe ivh or confirmed bacterial sepsis, which were only reported in the. Minimally invasive surfactant therapy with a gastric tube is. Discuss with the piper consultant 0 7 650 when considering surfactant therapy prior to transfer to a level 6 neonatal unit. Evidencebased guidelines for pain management in the neonatal intensive. Jan 06, 2020 respiratory distress syndrome, also known as hyaline membrane disease, occurs almost exclusively in premature infants. The use of surfactant replacement therapy in neonatal pneumonia has not been adequately studied.
Infants were eligible for mist if needing cpap pressure. Nov 08, 2012 evidence reveals similar results with regard to mortality and neonatal morbidity between the above two strategies. Pediatric and neonatal care guidelines stritch school of medicine. Pdf surfactant therapy in neonatal respiratory distress. Volume 54 number 3 surfactant therapy in late preterm infants 241. Official journal of the california perinatal association. The efficacy of surfactant replacement therapy is better when it is administered early in the course of disease. Therapy was deemed safe on a given day if the infant did not have to be removed from phototherapy due to needing physician treatment for sunburn or dehydration, due to persistent temperature instability defined as two or more episodes of temperatures 39. An infant from the latin word infans, meaning unable to speak or speechless is the more formal or specialised synonym for baby, the very young offspring of a human. Composite rd score comprising of five independent predictors of.
A newborn is, in colloquial use, an infant who is only hours, days, or up to one month old. Surfactant replacement was established as an effective and safe therapy for immaturityrelated surfactant deficiency by the early 1990s. Purpose and definitions surfactant therapy is given to minimise atelectasis and reduce the work of breathing. Summary pulmonary surfactant is a complex mixture of specific lipids, proteins and carbohydrates, which is produced in the lungs by type ii alveolar epithelial cells. Benefits should be seen within 2448 hours after institution of therapy. Methods an open feasibility study of mist was conducted at two sites. Randomized european multicenter trial of surfactant replacement therapy for severe neonatal respiratory. Neonatal respiratory distress syndrome, previously called hyaline membrane disease, is a respiratory disease affecting premature newborns. This therapy generally should only be reserved for intubated patients. Gray baby syndrome is caused by the neonatal use of.
Longterm effects of caffeine therapy for apnea of prematurity. Some new synthetic surfactants containing protein analogues, including chf5633, have recently been studied. Early administration of surfactant to intubated infants with respiratory distress syndrome rds is desirable. Surfactant therapy is the medical administration of exogenous surfactant. Antiretroviral therapy during the neonatal period ncbi nih. Respiratory distress syndrome and beyond article in the turkish journal of pediatrics 543. Discoveries that led to its development as a therapeutic agent span the whole of the 20th century but it was not until 1980 that the first successful use of exogenous surfactant therapy in a human population was reported.
Pdf surfactant therapy for neonatal respiratory distress. Transforming nicu care to provide comprehensive family support. Surfactant replacement therapy srt has a proven role in the treatment of neonatal respiratory distress syndrome and severe meconium aspiration syndrome in infants, and may have a role in the treatment of pediatric patients with ards. Commercial preparations type source composition dosing comments beractant survanta bovine lung mince dipalmitoyl phosphatidylcholine dppc, tripalmitin, spb neonates with nas. Surfactant function in neonates with respiratory distress.
These morbidities include deficits in oxygenation, the incidence of pulmonary air leaks pneumothorax and pulmonary interstitial. Management of neonatal respiratory distress syndrome. Surfactant replacement therapy should be considered in. Secondary surfactant deficiency also contributes to acute respiratory morbidity in latepreterm and term neonates with meconium aspiration syndrome, pulmonary. Respiratory distress syndrome rds due to surfactant deficiency is the most common cause of respiratory failure in preterm infants. Surfactant therapy and antibiotics in neonates with meconium aspiration syndrome. The presence of such molecules with surface activity had been suspected since the early 1900s and was finally. Respiratory distress syndrome clinical presentation. Surfactant therapy in neonatal respiratory distress syndrome article pdf available in indian pediatrics 318. Who recommendation on surfactant replacement therapy for.
Providing medicines adherence support to areas of high deprivation in england. Surfactant replacement therapy beyond respiratory distress syndrome in neonates article pdf available in indian pediatrics 533. A new clinical respiratory distress score for surfactant. Sep 26, 2016 administration of surfactant replacement therapy is strongly recommended in a clinical setting where properly trained personnel and equipment for intubation and resuscitation is readily available. Conditional recommendation only in healthcare facilities where intubation, ventilator care, blood gas analysis, newborn nursing care and monitoring are available based on moderatequality evidence. Surfactant replacement therapy srt has been shown to reduce mortality and air leaks in preterm neonates from highincome countries hics. Surfactant creates a continuously reforming surface layer. Of the 168 nbs who underwent physical therapy, 7 were born in the hospital 81. Surfactant therapy in preterm infants with respiratory distress syndrome and in nearterm or term newborns with acute rds.
Recommendations for neonatal surfactant therapy ncbi. The syndrome occurs when microscopic sacs called alveoli in infant lungs do not produce. Minimallyinvasive surfactant therapy mist contd 11. Both cpap and surfactant therapy are effective in management of preterm infants with rds. The incidence and severity of respiratory distress syndrome are related inversely to the gestational age of the newborn infant. Surfactant has revolutionized the treatment of respiratory distress syndrome and some other respiratory conditions that affect the fragile neonatal lung. This surface active material was later termed as surfactant, which is a. Mist failure was defined as need for early mechanical ventilation neonatal respiratory distress syndrome rds involved the insufficient production of pulmonary surfactant ps in premature infants, hyaline membrane diseasethe former name of the diseasewas replaced by rds since the description of the pathophysiology of rds, studies investigating remedies. Although newer delivery mechanisms and strategies are being studied, the classic surfactant administration paradigm consists of endotracheal intubation. According to established guidelines 64, mothers at risk of delivering babies. Click export csv or ris to download the entire page or use the checkboxes to select a subset of records to download. Fetuses, and neonates in research page 1 of 7 october 2011.
All guidelines should be read in conjunction with the disclaimer. Therapeutic hypothermia for neonatal encephalopathy. Surfactant replacement therapy for respiratory distress. Neonatal respiratory distress syndrome and its treatment. Aaed use in pregnancy management of babies exposed to antiepileptic drugs. The infants in the prophylaxis group received a 90mg intratracheal dose of an exogenous calflung surfactant extract at the time of delivery, whereas the infants in the rescue therapy group. Pdf surfactant replacement therapy for preterm and term. They showed that low surfactant protein values increased after surfactant administration, with an improvement in the clinical status of the infants, but the effects waned after 1 day. Because respiratory insufficiency may be a component of multiorgan dysfunction in. Effective detection and management of hypertension through community pharmacy in england. Newborn intensive care starship clinical guidelines. Tremendous progress has been made since the original. Continuing education course academy of neonatal nursing.
The large number of recommendations proposed by the npa workgroup can be distilled into ten essential recommendations to provide comprehensive family support as follows. Surfactant reduced both neonatal mortality and pulmonary air leaks by about 50%. The mixture is surface active and acts to decrease surface tension at the airliquid interface of the alveoli. Nicu, neonatal, hemorrhage, pulmonary hemorrhage, respiratory distress neonatal pulmonary hemorrhage purpose and goal. Rds in a premature infant is defined as respiratory distress requiring more than 30% oxygen delivered by positive pressure using either nasal cpap or an et tube with a chest radiograph that has. Poor outcomes are associated with pulmonary hemorrhage, so prompt recognition and treatment are critical.
Despite the south african sa arv treatment guidelines recommendation that abacavir. This guidance document is intended for researchers planning to involve pregnant women, fetuses, andor neonates as research subjects. Protocols 20182019 neonatal intensive care unit resident. Surfactant therapy for respiratory distress syndrome in. The surfactant is indicated in all neonates with rds.
The new england journal of medicine, 35719, 1893902. Neonatal respiratory distress syndrome involves shallow breathing, pauses between breaths that last a few seconds, or apnea, and a bluish tinge to the infants skin. The objective of this therapy is to allow significant weaning from high oxygen levels fio 2 0. Etiology of surfactant inactivation or dysfunction. Apr 08, 2016 after the initial phase of surfactant deficiency of the very preterm infant, inhibition and destruction of surfactant are common, the inflammation of the oxygen exposed preterm lung is probably important in the pathophysiology of bronchopulmonary dysplasia, and the adverse effects on surfactant function have led to trials of later surfactant supplementation, in the hope that. Late surfactant administration in very preterm neonates.
Exogenous surfactant therapy substantially reduces mortality and respiratory morbidity. The general data protection regulation gdpr governs the processing of personal information gathered from individuals while they are in the european union eu and parts of the eea european economic area, which currently includes iceland, lichtenstein and norway. Pdf surfactant replacement therapy beyond respiratory. Surfactant replacement therapy may be considered in. Surfactant replacement therapy for preterm and term neonates with respiratory distress. This page contains neonatology guidelines for nicu kemh and nicu pch. The use of sulfonamides has been implicated in the development of. In a study of 200 neonates, what percentage of babies experienced adverse drug reactions. A subgroup analysis of nearterm babies with respiratory failure from the prospective rct of lotze et al, showed that those who had sepsis and were treated with surfactants had a 40% decrease in the need for extracorporeal membrane oxygenation. The investigators intend to develop a method of minimally invasive surfactant therapy followed by early cpap mistcpap in preterm infants with high risk of rds for improving the outcomes and reducing the incidence of bpd. The use of surfactant replacement therapy in neonatal pneumonia has not been. Royal college of paediatrics and child health, 2000. Surfactant was the first drug developed solely for treatment of neonates. Surfactants used in this manner are typically instilled directly into the trachea.
Guidelines for surfactant administration surfactant. It can either be given as rescue treatment in neonates or prophylactically in all neonates surfactants will need ventilatory support. Surfactant therapy for respiratory distress syndrome in premature neonates. The standard treatment for jaundice using conventional phototherapy cpt with electric artificial blue light sources is often hampered by the lack of functional cpt devices due either to financial constraints. First dose needs to be given as soon as diagnosis of rds is made. Avery and mead in 1959, commented on the deficiency of a surface active material in the alveolar linings of the lungs of preterm babies with respiratory distress syndrome rds. Build an international network of ot clinicians and researchers working in this area to foster ongoing learning and practice development.
1251 241 463 173 1445 196 1374 1111 114 1477 996 1091 1024 269 561 775 297 1159 1414 1228 151 1059 639 1361 1253 288 430 617 154 1130 420 179 1336 21 650 234 1083 1016 1367 655 198 1384 1042